JP2019532084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532084A5 JP2019532084A5 JP2019520928A JP2019520928A JP2019532084A5 JP 2019532084 A5 JP2019532084 A5 JP 2019532084A5 JP 2019520928 A JP2019520928 A JP 2019520928A JP 2019520928 A JP2019520928 A JP 2019520928A JP 2019532084 A5 JP2019532084 A5 JP 2019532084A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- compound according
- heteroaryl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006735 (C1-C20) heteroalkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 claims 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 claims 1
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 230000005809 anti-tumor immunity Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229940029575 guanosine Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 229960000487 sorafenib tosylate Drugs 0.000 claims 1
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 201000009377 thymus cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022078657A JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
| JP2023162456A JP7749629B2 (ja) | 2016-07-06 | 2023-09-26 | 疾患の治療のための化合物、組成物、および方法 |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359039P | 2016-07-06 | 2016-07-06 | |
| US62/359,039 | 2016-07-06 | ||
| US201662363118P | 2016-07-15 | 2016-07-15 | |
| US62/363,118 | 2016-07-15 | ||
| US201662403530P | 2016-10-03 | 2016-10-03 | |
| US62/403,530 | 2016-10-03 | ||
| US201662411424P | 2016-10-21 | 2016-10-21 | |
| US62/411,424 | 2016-10-21 | ||
| US201762444141P | 2017-01-09 | 2017-01-09 | |
| US62/444,141 | 2017-01-09 | ||
| US201762462679P | 2017-02-23 | 2017-02-23 | |
| US62/462,679 | 2017-02-23 | ||
| US201762470746P | 2017-03-13 | 2017-03-13 | |
| US62/470,746 | 2017-03-13 | ||
| US201762508846P | 2017-05-19 | 2017-05-19 | |
| US62/508,846 | 2017-05-19 | ||
| PCT/US2017/040882 WO2018009648A1 (en) | 2016-07-06 | 2017-07-06 | Compounds, compositions, and methods for the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078657A Division JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532084A JP2019532084A (ja) | 2019-11-07 |
| JP2019532084A5 true JP2019532084A5 (enExample) | 2020-08-06 |
| JP7100227B2 JP7100227B2 (ja) | 2022-07-13 |
Family
ID=60913147
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520928A Active JP7100227B2 (ja) | 2016-07-06 | 2017-07-06 | 疾患の治療のための化合物、組成物、および方法 |
| JP2022078657A Pending JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
| JP2023162456A Active JP7749629B2 (ja) | 2016-07-06 | 2023-09-26 | 疾患の治療のための化合物、組成物、および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078657A Pending JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
| JP2023162456A Active JP7749629B2 (ja) | 2016-07-06 | 2023-09-26 | 疾患の治療のための化合物、組成物、および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11033569B2 (enExample) |
| EP (1) | EP3481402A4 (enExample) |
| JP (3) | JP7100227B2 (enExample) |
| KR (1) | KR102569881B1 (enExample) |
| CN (1) | CN109843302B (enExample) |
| AU (1) | AU2017293781B2 (enExample) |
| CA (1) | CA3029644A1 (enExample) |
| IL (1) | IL264049B2 (enExample) |
| MX (2) | MX392605B (enExample) |
| MY (1) | MY199689A (enExample) |
| SG (1) | SG11201811709WA (enExample) |
| TW (1) | TWI689514B (enExample) |
| WO (1) | WO2018009648A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221263T1 (hr) | 2016-03-18 | 2023-03-03 | Immune Sensor, Llc | Ciklički di-nukleotidni spojevi i postupci uporabe |
| KR102569881B1 (ko) * | 2016-07-06 | 2023-08-22 | 에프-스타 테라퓨틱스 인코포레이티드 | 질병 치료용 화합물, 조성물 및 방법 |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| TWI841526B (zh) | 2017-04-13 | 2024-05-11 | 荷蘭商賽羅帕公司 | 抗-SIRPα 抗體 |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| US11542293B2 (en) | 2017-11-10 | 2023-01-03 | Takeda Pharmaceutical Company Limited | Sting modulator compounds, and methods of making and using |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| US12291548B2 (en) | 2018-07-10 | 2025-05-06 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| US12370263B2 (en) | 2018-09-06 | 2025-07-29 | Daiichi Sankyo Company, Limited | Cyclic dinucleotide derivative based antibody-drug conjugates |
| WO2020057546A1 (zh) | 2018-09-21 | 2020-03-26 | 上海迪诺医药科技有限公司 | 环状二核苷酸类似物、其药物组合物及应用 |
| EP3873484B1 (en) | 2018-10-29 | 2023-08-23 | Venenum Biodesign, LLC | Novel sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| EP3873938A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody conjugates comprising sting agonists |
| EP3901161B1 (en) * | 2019-01-10 | 2025-01-22 | Shenzhen YING Biopharmaceutical Co., Ltd. | Cyclic dinucleotide prodrug molecule, preparation method therefor and application thereof |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3137119A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| EP3993834A1 (en) | 2019-07-05 | 2022-05-11 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| KR20220151630A (ko) | 2020-03-06 | 2022-11-15 | 다이이찌 산쿄 가부시키가이샤 | 신규 고리형 디뉴클레오티드 유도체를 포함하는 항체 약물 컨쥬게이트 |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| CN111909223A (zh) * | 2020-07-17 | 2020-11-10 | 清华大学 | 环二核苷酸共价修饰物及其制备方法和应用 |
| JP2023537066A (ja) | 2020-08-07 | 2023-08-30 | タンボ・インコーポレイテッド | トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| JP7798773B2 (ja) | 2020-09-02 | 2026-01-14 | 第一三共株式会社 | 新規エンド－β－Ｎ－アセチルグルコサミニダーゼ |
| MX2023005381A (es) | 2020-11-09 | 2023-05-23 | Takeda Pharmaceuticals Co | Conjugados de anticuerpo y farmaco. |
| CN118804983A (zh) | 2022-03-02 | 2024-10-18 | 第一三共株式会社 | 含Fc分子的制造方法 |
| EP4582106A1 (en) | 2022-08-29 | 2025-07-09 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including mutant fc region |
| WO2024076728A1 (en) * | 2022-10-06 | 2024-04-11 | Dana-Farber Cancer Institute, Inc. | Cyclic nucleotides and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) * | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| KR101137572B1 (ko) * | 2003-06-11 | 2012-05-30 | 이데라 파마슈티칼즈, 인코포레이티드 | 안정화된 면역조절 올리고뉴클레오티드 |
| JP4887284B2 (ja) * | 2004-03-15 | 2012-02-29 | デイビッド・ケイ・アール・カラオリス | 癌細胞の増殖を阻害するための、または癌細胞のアポトーシスを増大させるための方法 |
| US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| WO2011003025A1 (en) | 2009-07-01 | 2011-01-06 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| CN102199183B (zh) * | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
| AU2013271375B2 (en) | 2012-06-08 | 2018-03-22 | Aduro Biotech, Inc. | Compositions and methods for cancer immunotherapy |
| CN108542913A (zh) * | 2012-12-13 | 2018-09-18 | 艾杜罗生物科技公司 | 包含具有确定立体化学的环嘌呤二核苷酸的组合物及其制备和使用方法 |
| PT2934598T (pt) * | 2012-12-19 | 2018-07-24 | Univ Texas | Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero |
| EP2935616B1 (en) * | 2012-12-20 | 2018-02-28 | Hill's Pet Nutrition, Inc. | Pattern recognition receptor expression as a measure of systemic health |
| JP6153116B2 (ja) * | 2013-01-09 | 2017-06-28 | 国立大学法人東北大学 | トリアゾール連結型環状ジヌクレオチド類縁体 |
| CN103961306A (zh) | 2013-02-05 | 2014-08-06 | 日东电工株式会社 | 经皮给予用疫苗组合物 |
| WO2014179760A1 (en) * | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| PT2996473T (pt) * | 2013-05-18 | 2019-11-18 | Univ California | Composições e métodos para a ativação da sinalização dependente do ''estimulador de genes de interferão'' |
| CN103864910B (zh) * | 2014-03-03 | 2016-01-20 | 中国科学院南海海洋研究所 | 一种新型特异结合lps的贝类模式识别受体lrrp |
| KR20230097209A (ko) | 2014-03-12 | 2023-06-30 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
| MX2016015928A (es) | 2014-06-04 | 2017-03-20 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting. |
| PT3233882T (pt) | 2014-12-16 | 2020-01-21 | Kayla Therapeutics | Dinucleótidos cíclicos fluorados para a indução de citocinas |
| WO2016096577A1 (en) | 2014-12-16 | 2016-06-23 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| HK1248603A1 (zh) | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| JP6596146B2 (ja) | 2015-08-13 | 2019-10-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド化合物 |
| UY36969A (es) | 2015-10-28 | 2017-05-31 | Novartis Ag | Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon |
| KR101949108B1 (ko) | 2015-12-03 | 2019-02-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Sting의 조정제로서의 시클릭 푸린 디뉴클레오티드 |
| CN106540260A (zh) | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用 |
| US20180369268A1 (en) * | 2015-12-16 | 2018-12-27 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production |
| PE20181330A1 (es) | 2016-01-11 | 2018-08-20 | Innate Tumor Immunity Inc | Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| EP3423044A4 (en) | 2016-03-02 | 2019-11-20 | The Board of Regents of The University of Texas System | STING-ACTIVATING NANO VACCINE FOR IMMUNOTHERAPY |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| KR102569881B1 (ko) * | 2016-07-06 | 2023-08-22 | 에프-스타 테라퓨틱스 인코포레이티드 | 질병 치료용 화합물, 조성물 및 방법 |
| WO2018045204A1 (en) | 2016-08-31 | 2018-03-08 | Ifm Therapeutics, Inc | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| UA125223C2 (uk) | 2016-10-04 | 2022-02-02 | Мерк Шарп І Доум Корп. | СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| RU2019122602A (ru) | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака |
| US20200113924A1 (en) | 2016-12-20 | 2020-04-16 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| EP3585379A4 (en) | 2017-02-21 | 2020-12-02 | Board of Regents, The University of Texas System | CYCLIC DINUCLEOTIDES USED AS AGONISTS OF THE INTERFERON-DEPENDENT SIGNALING STIMULATOR |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| MX2019015468A (es) | 2017-06-22 | 2020-08-03 | Curadev Pharma Ltd | Moduladores de moleculas pequeñas de sting humana. |
| EP3642197A1 (en) | 2017-06-22 | 2020-04-29 | Curadev Pharma Limited | Heterocyclic small molecule modulators of human sting |
| JP2020524717A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの小分子調節因子 |
| US11707531B2 (en) * | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
-
2017
- 2017-07-06 KR KR1020197003440A patent/KR102569881B1/ko active Active
- 2017-07-06 JP JP2019520928A patent/JP7100227B2/ja active Active
- 2017-07-06 WO PCT/US2017/040882 patent/WO2018009648A1/en not_active Ceased
- 2017-07-06 CN CN201780054031.7A patent/CN109843302B/zh active Active
- 2017-07-06 MX MX2019000216A patent/MX392605B/es unknown
- 2017-07-06 US US16/315,472 patent/US11033569B2/en active Active
- 2017-07-06 IL IL264049A patent/IL264049B2/en unknown
- 2017-07-06 MY MYPI2019000212A patent/MY199689A/en unknown
- 2017-07-06 CA CA3029644A patent/CA3029644A1/en active Pending
- 2017-07-06 TW TW106122757A patent/TWI689514B/zh active
- 2017-07-06 AU AU2017293781A patent/AU2017293781B2/en active Active
- 2017-07-06 SG SG11201811709WA patent/SG11201811709WA/en unknown
- 2017-07-06 EP EP17824876.1A patent/EP3481402A4/en active Pending
-
2019
- 2019-01-07 MX MX2022006260A patent/MX2022006260A/es unknown
-
2021
- 2021-06-04 US US17/339,484 patent/US11744845B2/en active Active
-
2022
- 2022-05-12 JP JP2022078657A patent/JP2022106989A/ja active Pending
-
2023
- 2023-09-26 JP JP2023162456A patent/JP7749629B2/ja active Active